Brokerages Set Oculis Holding AG (NASDAQ:OCS) Target Price at $41.50

Oculis Holding AG (NASDAQ:OCS) has been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $43.50.

A number of research analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a report on Thursday, January 22nd. Lifesci Capital began coverage on Oculis in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 target price on the stock. JPMorgan Chase & Co. began coverage on Oculis in a research report on Friday, December 19th. They issued an “overweight” rating and a $38.00 price target for the company. Wall Street Zen raised Oculis from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, Chardan Capital reissued a “buy” rating and issued a $51.00 price objective on shares of Oculis in a research note on Tuesday, November 11th.

Key Oculis News

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Analysts raised price targets — HC Wainwright bumped its target to $44 (buy) and Needham raised its target to $40 (buy), giving the stock material upside vs. the current level; these upgrades can attract buying interest. Ticker Report
• Positive Sentiment: Company reported strong strategic progress in the Q4/2025 release: upcoming DIAMOND Phase 3 topline readout for OCS-01 in DME (Q2 2026), Breakthrough Therapy designation for Privosegtor advancing a large neuro-ophthalmology opportunity, and a clear R&D roadmap — these are meaningful clinical catalysts. Press Release
• Positive Sentiment: Balance sheet strength: Oculis reported $268.7M in cash and short-term investments at year-end 2025, which management says funds operations into 2029 — this reduces near-term financing risk and supports value for clinical milestones. Press Release
• Positive Sentiment: Oculis filed its 2025 financials and renewed a $100M at-the-market (ATM) equity program, giving the company optionality to raise capital opportunistically without immediate dilution — investors often view ATMs as a liquidity tool. TipRanks
• Neutral Sentiment: Company published notifications that RSUs vested and were settled for a director; this is routine insider compensation but can incrementally increase share count depending on settlement method. GlobeNewswire
• Negative Sentiment: Q4 earnings: Oculis reported a loss of $0.51/share, missing consensus (-$0.43) despite revenue topping estimates; EPS misses can pressure sentiment, especially for biotech names where near-term commercialization and cash burn matter. Earnings PDF

Oculis Price Performance

Oculis stock opened at $27.72 on Monday. The company has a market cap of $1.45 billion, a P/E ratio of -12.21 and a beta of 0.29. Oculis has a one year low of $14.00 and a one year high of $30.68. The business has a fifty day moving average of $25.89 and a two-hundred day moving average of $21.44. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.47.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 67.89%. The company had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.14 million. As a group, analysts predict that Oculis will post -2.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its holdings in Oculis by 100.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after buying an additional 1,000 shares during the last quarter. Aventura Private Wealth LLC purchased a new stake in Oculis during the 4th quarter worth about $80,000. Millennium Management LLC acquired a new position in Oculis in the 4th quarter valued at about $312,000. Bosun Asset Management LLC purchased a new position in Oculis in the 2nd quarter valued at about $378,000. Finally, Marshall Wace LLP purchased a new position in Oculis in the 2nd quarter valued at about $393,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.